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Type VI Ehlers±Danlos syndrome is a disease charac-
terized by disturbed lysine hydroxylation of collagen.
The disease is caused by mutations in lysyl hydroxy-
lase 1 gene and it affects several organs including the
cardiovascular system, the joint and musculoskeletal
system, and the skin. The skin of type VI Ehlers±
Danlos syndrome patients is hyperelastic, scars easily,
and heals slowly and poorly. We hypothesized that
providing functional lysyl hydroxylase 1 gene to the
®broblasts in and around wounds in these patients
would improve healing. In this study we tested the
feasibility of transfer of the lysyl hydroxylase 1 gene
into ®broblasts derived from rats and a type VI
Ehlers±Danlos syndrome patient (in vitro) and into
rat skin (in vivo). We ®rst cloned human lysyl hydro-
xylase 1 cDNA into a recombinant adenoviral vector
(Ad5RSV-LH). Transfection of human type VI
Ehlers±Danlos syndrome ®broblasts (about 20% of
normal lysyl hydroxylase 1 activity) with the vector
increased lysyl hydroxylase 1 activity in these cells to
near or greater levels than that of wild type, unaf-
fected ®broblasts. The adenoviral vector successfully
transfected rat ®broblasts producing both b-galacto-
sidase and lysyl hydroxylase 1 gene activity. We next
expanded our studies to a rodent model. Intradermal
injections of the vector to the abdominal skin of rats
produced lysyl hydroxylase 1 mRNA and elevated
lysyl hydroxylase 1 activity, in vivo. These data sug-
gest the feasibility of gene replacement therapy to
modify skin wound healing in type VI Ehlers±Danlos
syndrome patients. Key words: collagen/connective tissue/
inherited disease. J Invest Dermatol 116:602±605, 2001
T
ype VI Ehlers±Danlos syndrome (EDS VI) is a
recessively inherited disease of connective tissues
caused by mutations in the gene for lysyl hydroxylase
1 (LH) (Hyland et al, 1992; Hautala et al, 1993;
Heikkinen et al, 1994; 1997; Pousi et al, 1994; 1998;
Pajunen et al, 1998). LH catalyzes formation of hydroxylysine
residues that are required for cross-link formation and O-linked
glycosylation in collagens (Kivirikko and Pihlajaniemi, 1998).
Human LH consists of two identical subunits of 709 amino acids,
and the 40 kb gene for the enzyme contains 19 exons producing an
mRNA of 3.2 kb (Hautala et al, 1992; Heikkinen et al, 1994). LH
activity requires X-Lys-Gly sequence in collagenous substrates as
well as ferrous iron, ascorbate, 2-oxoglutarate, and molecular
oxygen as cofactors (Kivirikko and Pihlajaniemi, 1998).
Lack of LH activity in EDS VI patients yields structurally weak
collagen molecules causing severe musculoskeletal, cardiovascular,
and skin disease. Kyphoscoliosis, recurrent joint dislocations, ocular
complications, and arterial aneurysms can occur in these patients
(Wenstrup et al, 1989; Byers, 1994; Heim et al, 1998). The skin of
EDS VI patients may be hyperelastic and easily bruised. Poor
wound healing with subsequent scarring leads to secondary
complications. Unfortunately, little treatment is available for the
primary defect in these patients. Large doses of ascorbate, a cofactor
for the LH enzyme, has been shown to be bene®cial for some
patients, improving wound healing, bleeding time, and muscular
strength (Elsas et al, 1978; Dembure et al, 1987).
Gene replacement therapy may be feasible and bene®cial for
some of the cutaneous manifestations of EDS VI. Skin is easily
accessible and wound healing may and should bene®t from locally
administered LH activity. Heterozygous carriers of the defective
recessive gene who have diminished LH activity are healthy; this
suggests that even partial correction of the LH defect in EDS VI
patients may be bene®cial. In this study, we determined that an
adenoviral vector expressing human LH cDNA restores LH
enzyme activity in EDS VI patient skin ®broblasts, in vitro. We
also determined that this vector drives human LH mRNA
expression and enzymatic activity following intradermal injection
in rats, an animal with low endogenous skin LH activity
(Armstrong and Last, 1995).
MATERIALS AND METHODS
Cell culture Hydroxylysine-de®cient human skin ®broblasts
(CRL1195) (Sussman et al, 1974) were obtained from the American
Type Culture Collection (Manassas, VA). These cells and locally
established rat and human skin ®broblasts were cultured in Dulbecco's
modi®ed Eagle's medium (Gibco BRL, Rockville, MD) supplemented
with 10% fetal bovine serum, 28 mM ascorbate, 2 mM glutamate, 100 U
per ml penicillin, and 100 mg per ml streptomycin.
Construction of adenoviruses A 3040 nucleotide (nt) BamHI-
EcoRI fragment of human LH cDNA LH3A clone (Hautala et al, 1992)
containing polyadenylation signal was subcloned into adenovirus shuttle
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plasmid. This shuttle plasmid and the Ad5 backbone, sub360, were
cotransfected into HEK293 cells. Ad5RSV-LH was puri®ed using
conventional techniques (Jones and Shenk, 1979; Rowe et al, 1983) by
the University of Iowa Gene Transfer Vector Core. Cell lysates from
infected cells were evaluated for LH activity as described below.
Recombinant Ad5RSV-LH was plaque-puri®ed and concentrated using
CsCl centrifugation. Ad5RSVbgal has been described in detail elsewhere
(Davidson et al, 1994).
LH activity assay 5 3 106 cultured human skin ®broblasts or rat skin
samples (50±100 mg) were homogenized in a buffer containing NaCl
0.2 M, glycine 0.1 M, Triton X-100 0.1%, Tris-HCl (pH 7.5) 0.02 M at
4°C and centrifuged at 12,000g for 10 min. A 50 ml fraction of soluble
protein of cell lysates or tissue samples was mixed with collagenous
peptide substrate [[14C]lysine-labeled protocollagen prepared in cultures
of tendon cells (120,000 cpm) or nonradioactive GLKGEPGRKGEKG-
peptide in ®nal concentration of 0.5 mg per ml] and brought up to 1 ml
volume with reaction buffer [Tris-HCl (pH 7.8) 50 mM, bovine serum
albumin 1 mg per ml, catalase 0.1 mg per ml, dithiothreitol 0.1 mM,
ascorbate 1 mM, FeSO4 0.05 mM, 2-oxo-glutarate 0.5 mM]. The
mixture was incubated for 30 min at 37°C and then for 5 min at 95°C
(Kivirikko and MyllylaÈ, 1982). A fraction of reaction mixture was
hydrolyzed with 6 M HCl and analyzed for amino acid composition
using Applied Biosystems 421 AminoAcidAnalyzer. In experiments with
[14C]-protocollagen substrate, the amino acid analyzer was connected to
a fraction collector and fractions corresponding to lysine and
hydroxylysine residues were measured for radioactivity. The protein
concentration in each sample was determined (Bio-Rad Laboratories,
Hercules, CA) and LH activity is expressed as percentage of hydroxylated
lysine residues normalized for sample protein concentration.
Detection of mRNAs for LH Total RNA from cultured cells or
tissue samples was extracted using guanidium thiocyanate followed by
CsCl gradient centrifugation. RNA was treated with Dnase (Pharmacia
Biotech) for 1 h in order to remove contaminating DNA, after which
1 mg of RNA was reverse transcribed according to the manufacturer's
instructions (First-Strand cDNA Synthesis Kit, Pharmacia Biotech). LH
sequences were ampli®ed using oligonucleotide primers 5¢-
GGCATTGGGGATGAAGCTCT and 5¢-GGTTGGTCAGGAAC-
ATGAAC. This primer sequence is identical in rat and human cDNA
and both generate a 661 nt polymerase chain reaction (PCR) product.
The PCR mixture consists of 1 mM of each primer, 20 mM of
deoxynucleoside triphosphates, 1 IU DNA polymerase (DynazymeII,
Finnzymes, Helsinki, Finland), and buffer [1.5 mM MgCl2, 50 mM KCl,
0.1% Triton X-100, 10 mM Tris-HCl (pH 9.0)]. Ampli®cation was
performed at 94°C for 60 s, 55°C for 60 s, and 72°C for 60 s for a total
of 30 cycles in a thermocycler (Minicycler, MJ Research, Waltham,
MA). The rat cDNA sequence has a unique HindIII site; the human has
none. To distinguish between rat and human cDNA, we incubated the
PCR products at 37°C with HindIII (Pharmacia Biotech) for 2 h and
separated the products on 1.5% agarose gel. The 661 nt product was
considered human sequence and 155 and 506 nt fragments were
considered rat sequence. The ampli®cation protocol was not optimized
for quantitative analysis.
Virus injection into rat skin Sprague-Dawley rats were anesthetized
with intraperitoneal injection of fentanyl citrate 0.315 mg per ml,
midazolam 5 mg per ml, and ¯uanisone 10 mg per ml (1:1:1). 5 3 108
infectious units of Ad5RSV-LH virus in 50 ml volume were injected
into the abdominal dermis of rats. The rats were sacri®ced at indicated
times after the injection and skin samples were collected. The samples
were used for LH activity assay, mRNA preparation, or amino acid
analysis.
Rat skin amino acid analysis Rat skin samples were analyzed for
amino acid composition on days 0, 7, 14, or 28 after injection of
5 3 108 infectious units of Ad5RSV-LH or Ad5RSVbgal. The skin
biopsies were weighed and cut in small pieces, and the tissues were
sealed in tubes under a nitrogen atmosphere for hydrolysis with 6 M
HCl and 1 mM b-mercaptoethanol at 110°C for 24 h. Subsequently, the
samples were ®ltered with disposable 0.2 mm ®lter (Schleicher &
Schuell), lyophilized, and analyzed with Applied Biosystems 421
AminoAcidAnalyzer. The data are expressed as number of hydroxylated
lysine residues per 1000 amino acids.
Gene transfer ef®ciency in rat skin Five 3 108 infectious units of
Ad5RSVbgal in 50 ml volume were injected into the dermis of rat
abdominal skin in order to demonstrate gene transfer ef®ciency. The skin
samples were removed 48 h later, ®xed in 4% paraformaldehyde in
0.15 M sodium phosphate (pH 7.2), and incubated with X-gal (1 mg per
ml) in reaction buffer (2 mM MgCl2, 5 mM K3Fe(CN)6, 5 mM
K4Fe(CN)63H2O, 1 3 phosphate-buffered saline) at 37°C for 3 h. The
tissue samples were sectioned and analyzed with a microscope for b-
galactosidase expression.
RESULTS
Correction of LH activity in vitro We ®rst demonstrated that
the recombinant adenovirus carrying human LH cDNA (Ad5RSV-
LH) corrects the LH activity in EDS VI skin ®broblast cultures.
Figure 1 shows that cells transfected with the control virus
produced 0.4% 6 0.2% lysine hydroxylation (10%±15% of normal
skin ®broblasts), which equals previously reported LH activity
levels (Sussman et al, 1974). The ®broblasts transfected with 50 pfu
per cell Ad5RSV-LH produced 2.3% 6 0.1% hydroxylation (85%
of normal skin ®broblasts), and 100 pfu per cell further elevated the
hydroxylation level to 3.4% 6 0.2% (128% of normal skin
®broblasts). The LH activities shown in Fig 1 were obtained
using [14C]lysine-labeled protocollagen as a substrate, explaining
the low level of lysine hydroxylation. This is due to the fact that not
all lysine residues of type I collagen can be hydroxylated by LH.
The hydroxylation rate analyzed with collagenous peptide substrate
optimal for LH activity was signi®cantly higher (3.7% for control
virus, 18.6% for 50 pfu per cell, and 24.0% for 100 pfu per cell
Ad5RSV-LH). The data demonstrate that the Ad5RSV-LH
signi®cantly increased the LH activity in vitro in EDS VI skin
®broblasts.
Detection of LH mRNA We incubated cultured rat skin
®broblasts with Ad5RSV-LH and demonstrated human LH
mRNA in cell lysates 48 h later using PCR as described in
Materials and Methods. Our protocol ampli®ed a 661 nt band from
both rat and human sequences. The two species were distinguished
with a unique HindIII restriction site; the rat sequence was cut into
506 and 155 fragments whereas the human sequence was
undigested. Figure 2 (lane A) demonstrates that the 661 nt band
for human LH mRNA dominates in Ad5RSV-LH transfected rat
skin ®broblast cultures. The 661 nt band is clearly more intense
than the 506 nt band, suggesting strong human LH mRNA
expression from the gene transferred with Ad5RSV-LH. Control
cells that received equal amounts of Ad5RSVbgal showed
fragments corresponding to rat sequences (Fig 2, lane B). For lane
B, the amount of cDNA template was doubled in order to produce
the bands shown.
Figure 1. Correction of LH activity in vitro. LH activity in cultured
skin ®broblasts from an EDS VI patient and control human skin
®broblasts was determined using [14C]lysine labeled protocollagen. The
EDS cells were incubated with 50 pfu per cell of Ad5RSVbgal (bgal) or
50 or 100 pfu per cell of Ad5RSV-LH and the LH activity was
measured 48 h later. The enzyme activity was also determined in skin
®broblasts from a healthy control individual (control). The LH activity is
expressed as percentage of hydroxylated lysine residues in protocollagen
substrate and is normalized for cell lysate protein concentration. Each
condition was repeated at least three times. Error bars indicate standard
deviation (SD).
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Rat skin samples were analyzed for LH mRNA after Ad5RSV-
LH or Ad5RSVbgal injection. Lanes C and D in Fig 2 show a 661
nt band for human and a very faint 506 nt band for rat LH mRNA
after Ad5RSV-LH injection. Products of several ampli®cations
were pooled to demonstrate the rat LH mRNA in control
(Ad5RSVbgal) skin samples (lanes E and F). The data clearly
demonstrate that Ad5RSV-LH gene transfer produces speci®c
human LH expression in vivo. The ampli®cation protocol, how-
ever, was not optimized for quantitative analysis.
Adenoviral b-galactosidase gene transfer in rat skin In
order to demonstrate the recombinant adenovirus gene transfer into
rat skin, we injected 5 3 108 pfu of Ad5RSVbgal into abdominal
skin and the skin samples were stained for b-galactosidase
expression 48 h later. The skin sections that received
Ad5RSVbgal had blue nuclei demonstrating successful adenoviral
gene transfer. Figure 3 shows typical nuclear intensively blue b-
galactosidase staining.
LH activity in rat skin We injected 5 3 108 pfu of Ad5RSV-
LH in 50 ml volume into the abdominal skin of healthy Sprague-
Dawley rats. The ®rst rats were analyzed immediately for basal LH
activity using collagenous peptide substrate optimal for lysine
hydroxylation reaction. The activity was nearly undetectable with
the method used on day 0. On days 2 and 7 the LH activity was
clearly elevated, but on day 14 the LH activity was down to the
initial level in one animal whereas two rats continued to show
increased activity (Fig 4). The data demonstrate successful
adenoviral LH gene transfer although there was signi®cant
variation within each group of animals.
Hydroxylysine content in rat skin 5 3 108 pfu of Ad5RSV-
LH was injected into rat abdominal skin as described in Materials
and Methods. The skin samples were collected on days 0, 7, 14, or
28 after the injection and analyzed for amino acid composition.
The hydroxylysine content in skin samples was not signi®cantly
increased after the gene transfer (Table I) demonstrating that
endogenous LH activity is suf®cient to produce fully hydroxylated
skin collagen.
Figure 3. Adenoviral b-galactosidase gene transfer in rat skin.
Ad5RSVbgal (5 3 108 pfu in 50 ml volume) was injected into rat
abdominal skin in order to demonstrate adenoviral gene transfer. Tissue
samples were stained for b-galactosidase expression 48 h later.
Figure 2. Detection of LH mRNA. Cultured rat skin ®broblasts were
transfected with 50 pfu per cell of Ad5RSV-LH (lane A) or
Ad5RSVbgal (lane B) and analyzed 48 h later. A 661 nt fragment of
human and rat LH was ampli®ed from cDNA template as described in
Materials and Methods. HindIII digestion cuts the rat sequence into 155
and 506 nt fragments whereas the 661 nt human sequence ampli®cation
product remains undigested. On lane A, the 661 nt band for human LH
mRNA is signi®cantly stronger than the 506 nt product for rat
sequences, demonstrating strong expression from Ad5RSV-LH. Rat skin
samples injected with Ad5RSV-LH (lanes C and D) demonstrate human
LH mRNA (661 nt fragment) and a very faint 506 nt band for rat
sequences. Several ampli®cation reactions were pooled in order to
demonstrate the 506 nt band (lanes E and F) in control samples that
received Ad5RSVbgal. The arrows indicate positions of the 661, 506, or
155 nt markers.
Figure 4. LH activity in rat skin. LH activity in rat skin samples 0, 2,
7, or 14 d after gene transfer with Ad5RSV-LH (5 3 108 pfu in 50 ml
volume). The tissue samples were homogenized and LH activity was
analyzed from skin homogenate supernatants using optimal collagenous
peptide substrate on days 0, 2, 7, or 14 as described in Materials and
Methods. The data are expressed as percentage of hydroxylated lysine
residues in collagenous peptide substrate and normalized for protein
concentration in the tissue sample.
Table I. Skin amino acid composition was analyzed 0, 7,
14, or 28 d after Ad5RSV-LH or Ad5RSVbgal gene
transfera
Day Ad5RSV-LH Ad5RSVbgal
0 7.90 6 0.77
7 5.20 6 0.71 4.70 6 0.14
14 6.98 6 1.52 4.60 6 1.13
28 4.80 6 2.26 6.25 6 0.21
aThe table shows the number of hydroxylysine residues per 1000 amino acids 6
SD. Amino acid analysis was repeated at least three times in each condition.
Statistical difference is seen between the LH and control virus groups on day 14 (p
< 0.05); all other time points show no statistically signi®cant difference. There is
no signi®cant difference in lysine hydroxylation on day 14 compared with the in-
itial value on day 0.
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DISCUSSION
The most common mutation causing EDS VI is a large duplication
in the LH gene caused by homologous recombination between Alu
sequences in the introns 9 and 16 (Hautala et al, 1993; Pousi et al,
1994; Heikkinen et al, 1997). This duplication rearrangement is
estimated to account for 19% of the diseased LH alleles and it is also
found in the patient of this study (Pousi et al, 1994). The basal LH
activity in the skin ®broblasts of the patient is about 20% compared
to a healthy control individual (Sussman et al, 1974). Ad5RSV-LH
gene transfer elevates LH activity up to the levels found in normal
skin ®broblasts. It is probable that restoration of the LH function
leads to correction of mechanical properties of collagens that may
correlate with the severity of the disease symptoms in EDS VI.
There is no genetically defective animal model available for LH
de®ciency. This prevents us from addressing the question of the real
biologic effect on collagen function in LH-de®cient tissues in vivo.
Ad5RSV-LH gene transfer, however, produced human LH
mRNA and an increased LH activity in rat abdominal skin.
Analysis of skin collagen showed no signi®cant increase in lysine
hydroxylation after Ad5RSV-LH gene transfer. It should noticed,
however, that major skin collagens (types I and III) have a very low
number of hydroxylated lysine residues compared with other
collagen types (Kivirikko et al, 1992). Our experiment demon-
strates very clearly that endogenous LH activity is not a rate-
limiting component in lysine hydroxylation reaction in healthy skin
tissues.
Harvey et al demonstrated that ®rst generation adenoviral vector
persisted in human skin for at least 28 d with mild/moderate local
cellular in¯ammation (Harvey et al, 1999). In our study, the
elevated LH activity was still evident 2 wk after the virus injection
in two animals. This should allow reasonable time for initiation of
successful wound healing. Studies on adenoviral gene transfer have
demonstrated loss of transgene expression due to immune response
against the vector or the transgene product. It is probable that LH
overexpression will gradually diminish and it may not be possible to
achieve permanent correction with the vector used in this study.
Adenoviral vector can be used to test the principle of LH enzyme
replacement, but other vectors, such as AAV or recombinant
retroviruses, may provide lasting levels of expression.
Gene therapy for inherited diseases of connective tissue has
proved to be dif®cult, although there are some examples of
successful strategies (Vailly et al, 1998; Hengge et al, 1999; Seitz et
al, 1999; Somani et al, 1999). The majority of diseases of collagen
metabolism exhibit a dominant inheritance pattern and in general
the defective structural protein disturbs the function of a product of
healthy allele. In contrast to most inherited collagen diseases,
heterozygous relatives of EDS VI patients demonstrate that
products of defective LH allele should not interfere with the wild
type enzyme. Therefore, EDS VI is a good candidate disease to
consider for therapeutic gene transfer. Unfortunately, the major
symptoms of EDS VI as well as other inherited connective tissue
diseases arise during embryonic development and curative treat-
ment may no longer be possible in a newborn. Our data support
the possibility, however, that gene transfer may offer alleviation for
local symptoms of EDS VI.
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